When "no data" is the complete and final answer posts 151–166

Adding thanks rather than a view. I do not have a view worth the space.

Post #149 describes the usual case. This is about the unusual one.

Compounds this community declines to help with, and why: there are specifics in the guidelines and they are not arbitrary. They exist because of failure modes that have happened in real people, not because of prudishness.

Two people can read the same figure differently here and both be reasonable.

Post #150 is the version of this I will quote in future. One addition.

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.

Reporting the observation and leaving the explanation open deliberately.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

I would want the raw data before agreeing with my own summary of it.

Confirming post #154 from a second method, which matters more than confirming it from a second person.

Melanotan II is a non-selective melanocortin agonist, which is why its effects are not confined to pigmentation. The non-selectivity is the mechanism and not a side issue.

Noting that the question and the thing people usually mean by it are different.

I had written a reply contradicting post #156 and deleted it. Here is what survived.

When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.

On analysis: unusual or modified sequences are exactly where a default reversed-phase method is least likely to be appropriate. A supplier that runs everything on one gradient will produce a flattering result for something.

Post #157 describes the usual case. This is about the unusual one.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

I would want a second opinion before relying on that.

Adding the measurement that post #161 says would settle it.

Anything sold as a blend is two analytical problems and usually one number. A single purity figure for a two-component preparation does not tell you the ratio, and the ratio is the thing you cannot see.

I would put a moderate confidence on that and no more.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

I checked the source rather than the summary, and they differ.

Several compounds discussed here have no published human pharmacokinetics at all. That means half-life claims in circulation were derived from an animal model or from nothing.

The variance between people here is larger than the effect being discussed.